If you liked this article you might like

Biotech Movers: Synergy, Biogen, Insys
Why Biotech Investors Should Worry When Their Stocks Turn Boring
Valuation Is in the Eye of the Buyer: Cramer's 'Mad Money' Recap (Tuesday 4/4/17)
Why AbbVie Will be an Incredible Money-Making Machine in an Overvalued Stock Market